MARKET

CYCCP

CYCCP

Cyclacel Phar Pr
NASDAQ
9.99
-0.01
-0.10%
Closed 16:00 12/01 EST
OPEN
9.08
PREV CLOSE
10.00
HIGH
10.30
LOW
9.08
VOLUME
4.82K
TURNOVER
17.57K
52 WEEK HIGH
11.10
52 WEEK LOW
4.855
MARKET CAP
3.35M
P/E (TTM)
-5.4716
1D
5D
1M
3M
1Y
5Y
BRIEF-Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results
Reuters · 11/09 21:14
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce thi...
GlobeNewswire · 11/03 13:15
BRIEF-Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial Of Oral Fadraciclib
Reuters · 10/26 13:33
Cyclacel Reports Preliminary Data From Phase 1/2 Clinical Trial Of Oral Fadraciclib In Patients With Solid Tumors And Lymphoma At ENA 2022
Benzinga · 10/26 13:16
BRIEF-Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34Th Eortc-Nci-Aacr Symposium
Reuters · 10/13 13:21
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium October 26
 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology,
Benzinga · 10/13 13:17
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in fall of 2022 to highlight data update...
GlobeNewswire · 08/10 20:05
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce sec...
GlobeNewswire · 08/03 13:15
More
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.